· 23h · on MSN
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
· 1d · on MSN
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson: Q4 Earnings Snapshot
Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ
Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...
1d
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through 2029.
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim
Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 billion AI infrastructure plan. Netflix soared on strong subscriber numbers, while semiconductor shares surged on AI excitement.
NEW YORK — Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Jan. 13 that it will pay $132 in cash per share, or a 39 percent premium from Friday's closing price.
The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol on Jan. 6, 2021.
Wall Street's main indexes were set to open higher on Wednesday, with the tech-heavy Nasdaq leading gains, as investors cheered streaming giant Netflix's strong quarterly performance and President Donald Trump's multi-billion dollar support to bolster AI infrastructure.
"As a healthcare company with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease and heart failure," Chief Executive Joaquin Duato said in prepared remarks.
Wall Street closed higher, with the S&P 500 index scoring an all-time high. Blowout Netflix results and plans for $500b AI investment fuel gains.
President Donald Trump's boost to AI demand hopes is outweighing fresh tariff threats on China and the EU, as earnings season rolls on.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback